Compare GE Vernova Inc (GEV) vs Gilead Sciences, Inc. (GILD) Price & Performance

GE Vernova IncTrade

Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

GE Vernova Inc vs Gilead Sciences, Inc. — how do they compare? GE Vernova Inc trades at $1,027.6 (market cap $269.50B), while Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

	GEV	GILD
Market Cap	$269.50B	$168.35B
Sector	Technology	Health
52-Week High	$1.17K	$155.80
52-Week Low	$547.96	$110.56
Enterprise Value	$259.17B	$191.42B
Dividend Yield	0.2%	2.42%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Vernova Inc

GE Vernova (GEV) trades at $990.32, down 1.0% with bearish technical signals despite strong fundamentals. The company reported impressive Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust profitability with 23.04% net margin and 91.48% ROE. Recent news highlights GEV's $176 billion backlog and positioning in AI-driven power infrastructure demand, though valuation metrics remain elevated with P/E of 28.41 and EV/EBITDA of 84.47.

Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target, representing 28% upside. Key opportunities include AI data center power demand and nuclear energy expansion, while risks include premium valuation sensitivity and execution challenges in managing rapid growth across energy segments.

Gilead Sciences, Inc.

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GEV

GE Vernova benefits from AI-driven power and grid bottlenecks but faces high expectations at 28x 2028 earnings.Seeking Alpha · 6 hours agoNeutral Invesco S&P 500 Equal Weight Energy ETF rated Buy for balanced energy sector exposure amid oil market shifts.Seeking Alpha · 1 day agoBullish View details →

GILD

Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growthSeeking Alpha · 2 days agoBullish 2026 National ORBIE Awards honor top CIOs and CISOs across key industry categories in San Jose.Inspire Leadership Network · 4 days agoNeutral View details →

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.